Performance of “VIKIA Malaria Ag Pf/Pan” (IMACCESS®), a new malaria rapid diagnostic test for detection of symptomatic malaria infections by Monidarin Chou et al.
Chou et al. Malaria Journal 2012, 11:295
http://www.malariajournal.com/content/11/1/295RESEARCH Open AccessPerformance of “VIKIA Malaria Ag Pf/Pan”
(IMACCESSW), a new malaria rapid diagnostic test
for detection of symptomatic malaria infections
Monidarin Chou1†, Saorin Kim2†, Nimol Khim2, Sophy Chy2, Sarorn Sum2, Dany Dourng2, Lydie Canier2,
Chea Nguon3 and Didier Ménard2*Abstract
Background: Recently, IMACCESSW developed a new malaria test (VIKIA Malaria Ag Pf/Pan™), based on the
detection of falciparum malaria (HRP-2) and non-falciparum malaria (aldolase).
Methods: The performance of this new malaria rapid diagnostic test (RDT) was assessed using 1,000 febrile patients
seeking malaria treatment in four health centres in Cambodia from August to December 2011. The results of the
VIKIA Malaria Ag Pf/Pan were compared with those obtained by microscopy, the CareStart Malaria™ RDT
(AccessBioW) which is currently used in Cambodia, and real-time PCR (as “gold standard”).
Results: The best performances of the VIKIA Malaria Ag Pf/Pan™ test for detection of both Plasmodium falciparum
and non-P. falciparum were with 20–30 min reading times (sensitivity of 93.4% for P. falciparum and 82.8% for non-
P. falciparum and specificity of 98.6% for P. falciparum and 98.9% for non-P. falciparum) and were similar to those
for the CareStart Malaria™ test.
Conclusions: This new RDT performs similarly well as other commercially available tests (especially the CareStart
Malaria™ test, used as comparator), and conforms to the World Health Organization’s recommendations for RDT
performance. It is a good alternative tool for the diagnosis of malaria in endemic areas.Background
Now that artemisinin derivatives in combination with
partner drugs (artemisinin combination therapy (ACT))
are being used, parasitological confirmation has become
essential before treatment in routine malaria case man-
agement, in most countries endemic for malaria [1,2].
This ensures that anti-malarial drugs are only adminis-
tered to patients who need them, thereby limiting the
unnecessary use of inappropriate treatments. It also mini-
mizes the selection and spread of drug-resistant Plasmo-
dium falciparum parasites [3], particularly important in
areas where multidrug resistance is prevalent, such as
Southeast Asia [4-7].* Correspondence: dmenard@pasteur-kh.org
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reproduction in any medium, provided the orMicroscopic examination of blood films still remains
the gold standard for malaria diagnosis despite the re-
quirement for high-quality microscopes and equipment,
and for qualified personnel [8]. However, over the past
two decades, rapid diagnostic tests (RDTs) for malaria
have been developed for use in any situation where the
only realistic alternative was clinical diagnosis of malaria,
for example, at community level (e g, Village Malaria
Workers’ strategy in Cambodia). These diagnostic tests
are fast and easy to use, and do not require electricity or
complex equipment [9]. RDTs are now available from
around 60 manufacturers [10]. This profusion of suppliers
and the variable quality of RDT products marketed have
made it difficult for the policy makers of national malaria
control programmes to determine which tests are the
most suitable [11]. To address this issue, a global evalu-
ation programme to guide RDT procurement (product
testing) and assure RDT performance before and during
use in the field (lot testing) was launched in 2002 by the
WHO Regional Office of the Western Pacific (WPRO), intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Design of the VIKIA Malaria Ag Pf/Pan™ test.
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WHO/GMP), the UNICEF/UNDP/World Bank/WHO Spe-
cial Programme for Research and Training in Tropical Dis-
eases (TDR), the Foundation for Innovative New Diagnostics
(FIND), the Centers for Disease Control and Prevention
(CDC, Atlanta) and numerous other partners [12].
The malaria RDTs available are all based on the
same principle and like other lateral flow immune-
chromatographic tests, there are various formats (dipstick,
plastic cassette or card). They contain antibodies conju-
gated to colloidal gold particles, which bind specifically
with parasite antigens. Some of them are specific for
P. falciparum and detect the histidine-rich-2 protein
(HRP-2). Others combine HRP-2 detection with the
detection of antigens common to all species, such as
lactate dehydrogenase or aldolase (combo RDTs). Combo
RDTs can diagnose infections by P. falciparum or by non-
P. falciparum malaria parasites (Plasmodium vivax,
Plasmodium ovale and Plasmodium malariae) [13].
IMACCESS© is a company which aims to address pub-
lic health requirements by developing reliable diagnostic
tools responding to the constraints associated with use
in the field for populations in developing countries at af-
fordable prices [14]. The company recently developed
VIKIA Malaria Ag Pf/Pan™, a new malaria test. This new
RDT, based on the same technology as other tests,
allows detection of falciparum malaria (HRP-2) and
non-falciparum malaria (aldolase).
In this context, the objective of the study presented here
was to assess the performances of this new immunochro-
matographic test by following a conventional field evalu-
ation design including microscopic examination (thick
and thin blood film) and molecular detection (real-time
PCR) as gold standard methods for malaria diagnosis of
febrile, malaria-suspected patients seen at health centre
level. In addition, the VIKIA Malaria Ag Pf/Pan™ test was
also compared to another RDT widely used in Cambodia
and elsewhere (CareStart Malaria™, AccessBioW).
Methods
Rapid diagnostic tests
The VIKIA Malaria Ag Pf/Pan™ test kit (IMACCESS©,
Ref. 41 2499, Lot Number: V110727601, Lyon, France),
containing one package insert, 25 test cassettes in individ-
ual sealed pouches with a disposable specimen pipette and
a dessicant and one vial of running lysis buffer, was used
according to the manufacturer’s instructions. Briefly, a
5 μL aliquot of blood drawn from patients was added to
the sample well. Five drops of lysis buffer were then dis-
pensed into the buffer well (Figure 1). Results from the
test were interpreted at several times (readings after 10,
15, 20, 30 and 60 min). In parallel, the CareStart Mal-
aria™ test (Access Bio©, Ref. G0131, Lot Number: J191R,
New Jersey, USA) was also performed according to themanufacturer’s instructions and used to diagnose patients
as malaria infected.
Study population
Four different sites in Cambodia, all members of the
anti-malarial drug-resistance network (collaboration
between the Ministry of Health and the Institut Pasteur
du Cambodge) were selected (Figure 2): Veal Veng
health centre (in Pursat province), Veun Sai health
centre (in Rattanakiri province), Phnom Dek health
centre (in Preah Vihear province) and Takavit health
centre (in Sihanoukville province).
Malaria remains a public health problem at these sites,
and is mainly linked to the forests. Forest villagers in the
eastern and northern provinces are at high risk of mal-
aria, whereas elsewhere in the country malaria is an oc-
cupational disease with particular groups being at high
risk, including forestry workers, new settlers and mo-
bile/migrant populations moving into forested areas, and
soldiers and their families serving in the forests. The
prevalence is between 15% and 40% in villages near or in
forested areas, and between 0% and 3% in the plains and
rice field areas. The five human Plasmodium species all
co-exist in the Cambodia and P. falciparum is the most
frequent cause of malaria infections (prevalence ~70%).
The distributions of Plasmodium species have been
changing over recent years, with a particularly significant
increase in the incidence of P. vivax malaria cases (from
8% in 2000 to 23% in 2007). In low transmission areas, a
proportion of infections that are P. vivax is commonly
up to 50% [15-19].
In the four sites, patients with clinical symptoms of
malaria (fever ≥37.5°C) and with a prescription for mal-
aria diagnosis from a health care worker, agreeing to be
enrolled in the study (by signing the consent form), were
Figure 2 Map of Cambodia with the locations of the four selected health centres indicated.
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vere and complicated P. falciparum malaria according to
the definition of the World Health Organization (2001)
were excluded [20]. The study protocol was reviewed and
approved by the Ethics Committee of the Cambodian
Ministry of Health (No. 075 NECHR, 21 June, 2011).
Sample collection
Blood samples were collected by finger-prick and used
for malaria testing (both RDTs were tested in parallel by
two health staff blinded to each other). In addition, two
drops of blood were spotted onto Whatman 3 M filter
paper™ and individually stored in an envelope and a
plastic bag. Slides for thick and thin microscopic
examination were also prepared, and stored in appro-
priate boxes. Clinical and biological information were
recorded on an anonymous form to ensure patient
confidentiality. Filter papers and slide boxes were sentto the Institut Pasteur du Cambodge (IPC) in Phnom
Penh every week.
Laboratory procedures
At IPC, thick and thin blood smears were stained with
3% Giemsa for 30 min and analysed by light microscopy
by two experienced technicians without reference to
RDT results. A minimum of 200 consecutive fields was
checked in the thick blood film before classifying a slide
as negative. Parasites in thick blood films were counted
against 200 white blood cells. The parasite density was
estimated assuming 8,000 white blood cells/μL of blood.
One in 10 slides selected at random, and all slides corre-
sponding to discordance between the first two readings,
were read a third time by a third expert microscopist.
DNA was extracted from blood spots with Instagene
Matrix resin™ (Bio-Rad©, Marnes la Coquette, France),
according to the manufacturer’s instructions. Molecular
Table 1 Primers sequences and real-time PCR conditions used to detect Plasmodium species, Cambodia, 2011
Real-time PCR
name
Primer name Sequence (5'-3') Master mix Assay parameters Melt Parameters T° Melt peak
"Screening" RTPCRScreening2_F TGGAGTGGATGGTGTTTTAGA Hot FirePol EvaGreen qPCR
Mix Solis Biodyne 1X (#08-
24-00020), Primers 250 nM,
5 μl DNA template, total
volume 20 μl
95°C-15 min. 45 cycles:
95°C-15 sec./60°C-20 sec./
72°C-20 sec. 95°C-2 min.
68°C-2 min









RTPCRScreening2_F TGGAGTGGATGGTGTTTTAGA Hot FirePol DNA Pol. Solis
BioDyne 1.25 U (#01-02-01000),
dNTP 200 μM, MgCl2 2.5 mM,
Primers 250 nM, 5 μl DNA
template. Total volume 20 μl.
94°C −15 min. 20 cycles:
94°C-30 sec/ 58°C -1 min/







Hot FirePol EvaGreen HRM
Mix Solis Biodyne 1X (#08-
33-00001), Primers 250 nM,
5 μl template Primary PCR
products 1:1000, total
volume 20 μl
95°C-15 min. 40 cycles:
95°C-10 sec./62°C-20 sec./
72°C-25 sec. 95°C-1 min.
40°C-1 min








































Table 2 Comparison of real-time PCR and microscopy
results for 1,000 patients tested for malaria at health
centres, Cambodia, 2011
PCR results Microscopy results Total
Negative P. falciparum P. falciparum/
P. vivax
P. vivax
Negative 578 0 0 0 578
P. falciparum 6 110 3 2 121
P. falciparum/
P. vivax
6 43 4 9 62
P. vivax 21 0 0 216 237
P. vivax/
P malariae
0 0 0 2 2
Total 611 153 7 229 1000
Chou et al. Malaria Journal 2012, 11:295 Page 5 of 10
http://www.malariajournal.com/content/11/1/295detection and identification of Plasmodium parasites
involved two steps: Plasmodium was detected by a
“screening real-time PCR” with primers targeting theTable 3 Patients scoring positive for Plasmodium spp. by the
test and VIKIA Malaria Ag Pf/Pan™ test at several reading tim




CareStart Malaria RDT Negative 570
Pf & Pf/Non-Pf 3
Non-Pf 5
Non interpretable 0
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 10 min.
Negative 574
Pf & Pf/Non-Pf 1
Non-Pf 3
Non interpretable 0
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 15 min.
Negative 573
Pf & Pf/Non-Pf 2
Non-Pf 3
Non interpretable 0
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 20 min.
Negative 570
Pf & Pf/Non-Pf 2
Non-Pf 6
Non interpretable 0
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 30 min.
Negative 570
Pf & Pf/Non-Pf 2
Non-Pf 6
Non interpretable 0
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 60 min.
Negative 567
Pf & Pf/Non-Pf 5
Non-Pf 6
Non interpretable 0
Pf: P. falciparum; Pv: Plasmodium vivax; Pm: Plasmodium malariae; Non-Pf: PlasmodPlasmodium cytochrome b gene. Secondly, DNA sam-
ples identified as positive for Plasmodium were analysed
for malaria species by PCR with several pairs of specific
primers (P. falciparum, P. vivax/ Plasmodium knowlesi,
P. malariae and P. ovale) targeting the same gene
(Table 1). Molecular analyses were performed by techni-
cians blind to the results of microscopic and RDT
diagnoses.
Data analysis
Data were entered, processed, and analysed using Micro-
soft Excel 2010 software. The chi-squared test was used
to compare the performances of the different diagnostic
methods used (real-time PCR, microscopy and RDTs).
P-values <0.05 indicated statistically significant differ-
ences. For sensitivity and specificity, RDT results were
compared with microscopy and real-time PCR results.
Sensitivity was calculated as the proportion of positivereference method (microscopy/PCR), CareStart Malaria™
es (10, 15, 20, 30 and 60 minutes), Cambodia, 2011
d real-time PCR results Total
Pf Pf/Pv Pv Pv/Pm
121 62 237 2 1000
(12.1%) (6.2%) (23.7%) (0.2%) (100%)
8 8 33 0 619
113 46 6 0 168
0 8 198 2 213
0 0 0 0 0
12 16 89 1 692
104 41 3 0 149
3 5 143 1 155
2 0 2 0 4
9 9 54 0 645
111 46 4 0 163
1 7 179 2 192
0 0 0 0 0
8 8 44 0 630
113 46 6 0 167
0 8 187 2 203
0 0 0 0 0
8 8 40 0 626
113 46 6 0 167
0 8 191 2 207
0 0 0 0 0
7 8 40 0 622
114 46 7 0 172
0 8 190 2 206
0 0 0 0 0
ium non-falciparum.
Table 4 Frequencies of false positive, false negative and misclassified results obtained from RDTs with reference to
microscopy and PCR results (including non-interpretable data), Cambodia, 2011
RDTs Frequency of Total
False positive False negative Misclassified Non-interpretable
CareStart Malaria RDT 0.8 4.9 1.4 0 7.1
VIKIA Malaria Ag
Pf/Pan RDT
Reading time 10 min. 0.4 11.8 1.1 0.4 13.7
Reading time 15 min. 0.5 7.2 1.2 0 8.9
Reading time 20 min. 0.8 6.0 1.4 0 8.2
Reading time 30 min. 0.8 5.6 1.4 0 7.8
Reading time 60 min. 1.1 5.5 1.5 0 8.1
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parasites as identified by microscopy or real-time PCR.
Specificity was calculated as the proportion of negative
test results among samples scoring negative by thick blood
film or real-time PCR tests. Positive and negative predict-
ive values were the proportion of true-positive results
among all positive samples and the proportion of true
negative results among all negative samples, respectively.Results
From August to December 2011, 1,000 patients (Preah
Vihear, N = 300, Veal Veng, N = 250, Ratanakiri, N = 300
and Takavit, N = 150) with an age range of one to
70 years (mean ± SD age = 22.4 ± 12.9 years; 7.0% <5 years
of age, 18.0% between five and 14 years of age, and
75.0% >15 years of age) were recruited. The male/female
ratio was 2.1/1. The mean ± SD axillary temperature was
38.1 ± 0.9°C (range = 37.5–41.5°C) and the mean± SDTable 5 Diagnostic performances of the CareStart Malaria™ te
reading times (10, 15, 20, 30 and 60 min) for detection of Pla
RDT diagnostic performa
Sensitivity (95%CI)
CareStart Malaria RDT Pf 93.4% (87.4-97.1%)
Non-Pf 85.8% (80.7-90.0%)
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 10 min.
Pf 89.7% (82.6-94.6%)
Non-Pf 61.5% (54.9-67.8%)
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 15 min.
Pf 92.5% (86.2-96.5%)
Non-Pf 77.0% (71.1-82.2%)
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 20 min.
Pf 93.4% (87.4-97.1%)
Non-Pf 81.1% (75.5-85.9%)
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 30 min.
Pf 93.4% (87.4-97.1%)
Non-Pf 82.8% (77.4-87.4%)
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 60 min.
Pf 94.2% (88.4-97.6%)
Non-Pf 82.7% (77.3-87.4%)
Pf: P. falciparum; Non-Pf: Plasmodium non-falciparum.
PPV: Positive predictive value; NPV: Negative predictive value.parasitaemia density was 13,455 ± 52,694 parasites/μL
(range = 20–582,500 parasites/μL).
Microscopy results showed that 389 (38.9%) of the
1,000 patients had malaria. Plasmodium falciparum was
present in 39.5%, P. vivax in 58.8% and both P. falcip-
arum and P. vivax (mixed infections) in 1.5% of the
positive specimens. A total of 92 discordant results
(9.2%) were found between microscopy and real-time
PCR (Table 2). Some 32 cases (3.2%) classified as nega-
tive by microscopy were positive by real-time PCR (sub-
microscopic parasitaemia: six P. falciparum, six mixed P.
falciparum/P. vivax and 21 P. vivax). In addition, 59
samples were misclassified by microscopy: 54 were clas-
sified as single infections by microscopy (43 P. falcip-
arum, 11 P. vivax) but found to be mixed infections by
real-time PCR (52 mixed P. falciparum/P. vivax and two
mixed P. vivax/P. malariae); three cases classified as
mixed P. falciparum/P. vivax infections were identified
as single P. falciparum infections by real-time PCR; twost and the VIKIA Malaria Ag Pf/Pan™ test at several
smodium spp. in field study patients, Cambodia, 2011
nce
Specificity (95%CI) PPV (95% CI) NPV (95% CI)
98.6% (97.3-99.40%) 93.4% (87.4-97.10%) 98.6% (97.3-99.4%)
99.1% (98.0-99.7%) 97.6% (94.4-99.2%) 94.5% (92.4-96.2%)
99.3% (98.3-99.8%) 96.3% (90.8-99.0%) 97.9% (96.4-98.9%)
99.5% (98.5-99.9%) 97.9% (94.1-99.6%) 86.4% (83.6-89.0%)
99.1% (98.0-99.7%) 95.7% (90.2-98.6%) 98.4% (97.1-99.3%)
99.5% (98.5-99.9%) 98.4% (95.3-99.7%) 91.4% (88.9-93.5%)
98.6% (97.3-99.40%) 93.4% (87.4-97.10%) 98.6% (97.3-99.4%)
98.9% (97.7-99.6%) 96.9% (93.4-98.9%) 92.8% (90.5-94.7%)
98.6% (97.3-99.40%) 93.4% (87.4-97.10%) 98.6% (97.3-99.4%)
98.9% (97.7-99.6%) 97.0% (93.6-98.9%) 93.4% (91.2-95.3%)
98.1% (96.6-99.0%) 91.2% (84.8-95.5%) 98.8% (97.5-99.5%)
98.9% (97.7-99.6%) 97.0% (93.5-98.9%) 93.4% (91.1-95.2%)
Figure 3 Comparative representation of the diagnostic performances of the CareStart Malaria™ test and the VIKIA Malaria Ag Pf/Pan™
test at several reading times (10, 15, 20, 30 and 60 minutes) for detection of Plasmodium spp. in field study patients, Cambodia, 2011.
Table 6 Diagnostic performance of the CareStart Malaria™ test and the VIKIA Malaria Ag Pf/Pan™ test at several
reading times (10, 15, 20, 30 and 60 minutes) for different levels of Plasmodium spp. parasitaemia, Cambodia, 2011
Parasitaemia/μl of blood CareStart Malaria RDT VIKIA Malaria Ag Pf/Pan
RDT - Reading time 10 min.
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 15 min.
Pf Non-Pf Pf Non-Pf Pf Non-Pf
Sub-microscopic Sensitivity 16.7% 0.0% 16.7% 0.0% 16.7% 0.0%
< 100 Sensitivity 75.0% 68.7% 75.0% 46.7% 75.0% 50.0%
101-500 Sensitivity 71.4% 80.9% 57.1% 36.4% 57.1% 45.5%
501-1,000 Sensitivity 100.0% 72.7% 90.0% 36.4% 100.0% 72.7%
1,001-5,000 Sensitivity 100.0% 100.0% 100.0% 72.0% 100.0% 88.2%
5,001-10,000 Sensitivity 100.0% 100.0% 90.5% 74.3% 100.0% 92.1%
10,001-50,000 Sensitivity 100.0% 100.0% 100.0% 77.9% 100.0% 98.5%
50,001-100,000 Sensitivity 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
> 100,000 Sensitivity 100.0% - 95.5% - 100.0% -
Parasitaemia/μl of blood VIKIA Malaria Ag Pf/Pan
RDT - Reading time 20 min.
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 30 min.
VIKIA Malaria Ag Pf/Pan
RDT - Reading time 60 min.
Pf Non-Pf Pf Non-Pf Pf Non-Pf
Sub-microscopic Sensitivity 16.7% 0.0% 16.7% 0.0% 16.7% 0.0%
< 100 Sensitivity 75.0% 53.3% 75.0% 53.3% 75.0% 56.2%
101-500 Sensitivity 71.4% 57.1% 71.4% 61.9% 85.7% 61.9%
501-1,000 Sensitivity 100.0% 72.7% 100.0% 81.8% 100.0% 81.8%
1,001-5,000 Sensitivity 100.0% 94.0% 100.0% 98.0% 100.0% 98.0%
5,001-10,000 Sensitivity 100.0% 97.4% 100.0% 97.4% 100.0% 97.4%
10,001-50,000 Sensitivity 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
50,001-100,000 Sensitivity 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
> 100,000 Sensitivity 100.0% - 100.0% - 100.0% -
Pf: P. falciparum; Non-Pf: Plasmodium non-falciparum.
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Figure 4 Comparative representation of the sensitivities of the CareStart Malaria™ test and the VIKIA Malaria Ag Pf/Pan™ test at
several reading times (10, 15, 20, 30 and 60 minutes) for different levels of Plasmodium spp. parasitaemia. Results for Plasmodium
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Figure 5 Comparative representation of the sensitivities of the CareStart Malaria™ test and the VIKIA Malaria Ag Pf/Pan™ test at
several reading times (10, 15, 20, 30 and 60 minutes) for different levels of Plasmodium spp. parasitaemia. Results for non-P. falciparum
infections, Cambodia, 2011.
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to be single P. falciparum infections by real-time PCR.
Details concerning patients positive for Plasmodium
spp. by real-time PCR, microscopy, CareStart Malaria™
and VIKIA Malaria Ag Pf/Pan™ tests at several reading
times (10, 15, 20, 30 and 60 min) are shown in Table 3.
Frequencies of false positives, false negatives and misclas-
sified results obtained from RDTs with reference to mi-
croscopy and PCR results (including non-interpretable
data; Table 4) indicated that the best reading times were
20–30 min for the VIKIA Malaria Ag Pf/Pan™ test. Diag-
nostic performances of both RDTs are shown in Table 5
and Figure 3. Sensitivities for different levels of Plas-
modium spp. parasitaemia are summarized in Table 6,
Figure 4 for P. falciparum infections and Figure 5 for
non-P. falciparum infections.
Discussion
This study reports the first evaluation of the perform-
ance of the VIKIA Malaria Ag Pf/Pan™, a new immuno-
chromatographic test developed by IMACCESSW, using
a combination of microscopy and real-time PCR as
reference methods for classification of samples. This ap-
proach had the advantage of combining the high sensi-
tivity (especially at low parasite density) and specificity
(to correctly identify the parasite species) of real-time
PCR, with the possibility of estimating parasite density
by microscopy. As expected, more positive samples were
found using real-time PCR than microscopy (+ 8.5%,
38.9% vs 42.2%), CareStart Malaria™ test (+9.7%, 38.1%
vs 42.2%) or VIKIA Malaria Ag Pf/Pan™ test (from
+10.4% for 60 min reading time to +27.0% for 10 min
reading time, 30.8% and 37.8%, respectively vs 42.2%). A
similar trend was also found for a greater sensitivity of
microscopy by expert microscopists than malaria RDTs:
2.0% more positive samples by microscopy than CareS-
tart Malaria™ test (38.8% vs 38.1%) and 2.8% (60 min
reading time) to 20.8% (10 min reading time) more than
with the VIKIA Malaria Ag Pf/Pan™ test (38.8% vs 37.8%
and 30.8%, respectively).
The sensitivity (and the frequency of false negatives) of
the VIKIA Malaria Ag Pf/Pan™ test increased with reading
time, from 89.7% for P. falciparum detection and 61.5%
for non-P. falciparum detection (10 min) to 94.2% for
P. falciparum detection and 82.7% for non-P. falciparum
detection (60 min). The specificity (and the frequency of
false positives) decreased with reading time from 99.3% for
P. falciparum detection and 99.5% for non-P. falciparum
detection (10 min) to 98.1% for P. falciparum detection
and 98.9% for non-P. falciparum detection (60 min).
The best performances of the VIKIA Malaria Ag Pf/Pan™
test for both P. falciparum and non-P. falciparum detec-
tion were observed at 20–30 min (sensitivity: 93.4% for
P. falciparum and 81.1%-82.8% for non-P. falciparum;specificity: 98.6% for P. falciparum and 98.9% for non-
P. falciparum). Using these reading times, the perform-
ance of the VIKIA Malaria Ag Pf/Pan™ test was similar
to those of the CareStart Malaria™ test or those found
in previous studies [21-26].
Moreover, as has been previously reported, the sensi-
tivities of both malaria RDT decreased with the level of
the parasitaemia [23,26-30]: for P. falciparum, the sensi-
tivity of the both tests started to decrease at levels of
parasitaemia < 500 parasites/μL (100% above 500 para-
sites/μL) and for non-P. falciparum, the sensitivity of the
CareStart Malaria™ test and the VIKIA Malaria Ag Pf/Pan™
test started to decrease below 1,000 parasites/μL or below
10,000 parasites/μL, respectively. False negative results for
both malaria RDT were only found in P. falciparum sam-
ples containing <250 parasites/μL and in non-P. falciparum
samples with <1,000 parasites/μL.
According to WHO recommendations for RDT per-
formances [31], sensitivity of the VIKIA Malaria Ag Pf/
Pan™ test (except when the time reading was 10 min)
was greater than 95%, excluding samples with a parasit-
aemia <100 parasites/μL. As observed for the CareStart
Malaria™ test, the VIKIA Malaria Ag Pf/Pan™ test was
easy to use and interpret and simple to store with no
cold chain requirement.Conclusions
In conclusion, this new RDT performs similarly well as
other commercially available tests (and in particular the
CareStart Malaria™ test, used as comparator), and con-
forms to WHO recommendations for RDT performance.
It appears to be a satisfactory alternative tool for the
diagnosis of malaria in endemic areas.
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